Trinity Biotech plc (Nasdaq:TRIB), a leading developer and
manufacturer of diagnostic products for the point-of-care and
clinical laboratory markets, today announced results for the
quarter ended March 31, 2015.
Quarter 1 Results
Total revenues for Q1, 2015 were $25.2m, an increase of $0.2m
when compared with Q1, 2014. However, revenues this quarter were
particularly impacted by foreign exchange movements due to the
strengthening of the US dollar against a range of currencies.
Excluding this currency effect, revenues would have increased to
$26.4m, representing an increase of 6%.
Point-Of-Care revenues for Q1, 2015 increased by 2% (or 4.4% on
a constant currency basis) when compared to Q1, 2014. This increase
is due to the impact of the initial sales of the newly CLIA waived
Syphilis rapid test.
Clinical Laboratory revenues increased from $20.5m to $20.7m,
which represents an increase of approximately 1% compared to Q1,
2014. However, on a constant currency basis Q1, 2015 revenues were
$21.7m – an increase of 6%. The principal factors contributing to
this increase were the continued growth in Premier revenues due to
higher reagent pull-through, in addition to higher autoimmune
revenues from Immco.
Revenues for Q1, 2015 by key product area were as follows:
|
|
2014 |
2015 |
2015 |
Increase/ |
|
Quarter 1 |
Quarter 1 |
Quarter 1 |
(decrease) |
|
|
|
FX adjusted* |
|
|
US$'000 |
US$'000 |
US$'000 |
% |
Point-of-Care |
4,506 |
4,585 |
4,702 |
4.4% |
Clinical Laboratory |
20,519 |
20,655 |
21,742 |
6.0% |
Total |
25,025 |
25,240 |
26,444 |
5.7% |
|
|
|
|
|
* quarter 1, 2015 revenues have
been recalculated on a constant currency basis using the exchange
rates prevailing in Q1, 2014 |
Whilst exchange rate movements have adversely impacted revenues
this quarter, they have had a favourable impact on the company's
cost base. The company has an effective natural currency hedge
between revenues and costs, thus the exchange rate movements this
quarter had no impact on the company's overall profit. In
summary, the extent to which revenues and gross profit have been
adversely impacted by the stronger dollar was offset by lower
foreign currency denominated SG&A expenses.
The gross profit for Q1, 2015 amounted to $12.1m, which equates
to a gross margin of 47.9%. This represents a slight reduction from
48.6% in Q1, 2014, which is partly explained by the impact of the
abovementioned currency movements.
Research and Development expenses were consistent with Q1, 2014
at $1.0m, whilst Selling, General and Administrative (SG&A)
expenses also remained largely in line with Q1, 2014 at
$6.3m. The latter includes the favourable impact of the
stronger dollar, offset by increased sales and marketing costs,
mainly relating to Meritas.
Operating profit for the quarter was $4.3m, compared to $4.5m in
Q1, 2014. Operating margin for the quarter was 17.2%. Profit before
tax for the quarter was $4.3m, whilst profit after tax was
$4.0m. Meanwhile, EPS for Q1, 2015 was 17.4 cents. However,
this quarter we incurred over $0.6m of SG&A costs related to
Meritas, against which we have no matching revenues. Excluding such
costs would have resulted in after tax profits of approximately
$4.6m or over 20 cents per ADR.
EBITDA and before share option expense for the quarter increased
from $6.0m to $6.2m – an increase of over 3%.
The tax charge for the quarter was $0.3m which represents an
effective tax rate of 7%. This highly competitive rate has
been driven by the low rate of corporation tax in Ireland and the
availability of R&D tax credits in both Ireland and North
America.
Other Developments
Cardiac Update
In February 2015, the company announced that, after a brief
cessation, it had recommenced US clinical trials on its Troponin I
point-of-care product. The clinical trial is running at 12,
geographically diverse, trial sites across the USA and is currently
recruiting just under 70 patients per week. Furthermore, the actual
rate of myocardial infarctions is tracking slightly higher than
expected. Consequently, the project remains on course to have
data collection, subsequent adjudication and statistical analysis
all completed during the month of July with FDA submission planned
for August, 2015. The product continues to demonstrate the
excellent clinical performance demonstrated in our European CE
marking trials and in the independent clinical evaluation carried
out at Hennepin County Medical Center, Minneapolis and published at
AACC in July, 2014. Furthermore, European evaluations are well
underway along with product registrations in a number of countries
including both China and Brazil.
In relation to Meritas BNP, the company expects USA clinical
trials to be completed in September, 2015 with FDA submission
following immediately thereafter. Finally, data from an
independent clinical evaluation of the Meritas BNP product, carried
out by Dr. Apple at Hennepin County, has been accepted for
publication at the AACC meeting in Atlanta on July 26, 2015. This
data indicates excellent clinical performance characteristics for
Meritas BNP.
Appointment of new Chief Scientific Officer
Trinity Biotech is pleased to announce the appointment of Eric
Brouwer, PhD, as Chief Scientific Officer (CSO), and Vice President
Cardiac. Previously, Dr Brouwer led product development at Abbott
Point-of-Care. He brings extensive leadership experience in
creating, developing and launching FDA approved products for the
point-of-care in vitro diagnostics market. At Abbott, he was a
member of the Scientific Governing Board and was the recipient of
the Abbott Chairman's Award (2007) for the FDA 510(k) waiver
clearance of a point-of-care Basic Metabolic test panel. As CSO and
VP Cardiac, Dr Brouwer will lead product development in our Cardiac
Marker and Infectious Diseases Point-of-Care businesses.
Dr Jim Walsh, who previously held the positions of both Business
Development Director and CSO, will now focus on business
development with an emphasis on the identification and execution of
suitable acquisition targets.
Fundraising and Shelf Registration
The company raised $115m in April from the issuance of 4%
exchangeable senior notes repayable in 2045. However, due to the
inclusion of a series of put and call options, earlier redemption
is possible. The initial offering of $100m included a 30-day option
to purchase an additional $15m of the notes, an option that was
fully exercised. The net proceeds from the offering for Trinity
amounted to $110.5m after deducting the associated costs of the
transaction. The Company's intention is that these proceeds will be
used for future acquisitions.
On April 22, the company filed a $200m shelf registration with
the SEC. This in no way represents an intention to issue equity at
this time, but rather reflects the implementation of a new policy
to maintain a live shelf registration at all times.
Annual Dividend
The company is proposing a dividend of 22 cents per ADR (5.5
cents per 'A' ordinary share), which is consistent with the
dividend paid in 2014. The payment of this dividend is subject to
shareholder approval, which will be sought at the company's
forthcoming AGM to be held on June 5, 2015. Subject to this
approval being granted, the record date will be June 9, 2015 and
payment will follow approximately 3 weeks later.
Comments
Commenting on the results, Kevin Tansley, Chief Financial
Officer, said "Revenues increased by $0.2m to $25.2m this quarter.
However, taking into account exchange rate movements this
represents an increase of nearly 6% on a constant currency basis.
This growth was largely attributable to our very successful Premier
offering and higher Immco autoimmune sales. Profit for the period
amounted to $4m which represent an EPS of 17.4 cents whilst EBITDA
and before share option expense increased to $6.2m."
Ronan O'Caoimh, CEO, stated that "During quarter 1, the business
performed well, effectively achieving growth of 6%, with Premier
and Immco both performing strongly. We are also very excited with
the rapid syphilis market opportunity in the USA. Whilst sales to
date have been modest, we are delighted with the enormous level of
interest the product has generated, with virtually every state and
major city health department in the USA having expressed an
interest in using the test. This augurs very well for the future of
this product, though given the nature of government spending, it
will take some time before we achieve a significant level of
sales.
We are also delighted with the progress in our Troponin I
clinical trials. The product continues to demonstrate excellent
clinical performance and we expect to submit the trial data to the
FDA in August of this year. In addition, the registration process
is well underway in a number of other countries, such as China and
Brazil, both of which represent very significant market
opportunities for Trinity.
In April, the company completed a significant fundraising in the
form of 30 year 4% exchangeable senior notes, which yielded
$110.5m, net of expenses. The company intends to use these funds to
make strategic acquisitions. The company has a history of
identifying and effectively integrating high quality acquisitions.
We will focus on acquisitions which will be earnings enhancing and
cash flow positive, have distinct operational synergies with our
existing business, whilst at the same time demonstrating strong
growth potential.
Today we are also proposing an annual dividend of 22 cents per
ADR. This is consistent with the dividend declared in
2014.
Finally, I would like to welcome Dr. Eric Brouwer to the company
in the role of Chief Scientific Officer and VP Cardiac. Eric
has a vast amount of experience, particularly in the area of
developing and launching cardiac products and will be a most
valuable addition to our team and I have no doubt that he will make
a very significant contribution to the launch of our new Meritas
range of products."
Litigation Reform Act of 1995. Investors are cautioned that such
forward-looking statements involve risks and uncertainties
including, but not limited to, the results of research and
development efforts, the effect of regulation by the United States
Food and Drug Administration and other agencies, the impact of
competitive products, product development commercialisation and
technological difficulties, and other risks detailed in the
Company's periodic reports filed with the Securities and Exchange
Commission.
Trinity Biotech develops, acquires, manufactures and markets
diagnostic systems, including both reagents and instrumentation,
for the point-of-care and clinical laboratory segments of the
diagnostic market. The products are used to detect infectious
diseases and to quantify the level of Haemoglobin A1c and other
chemistry parameters in serum, plasma and whole blood. Trinity
Biotech sells direct in the United States, Germany, France and the
U.K. and through a network of international distributors and
strategic partners in over 75 countries worldwide. For further
information please see the Company's website:
www.trinitybiotech.com
Trinity Biotech
plc |
Consolidated Income
Statements |
|
|
|
(US$000's except share data) |
Three Months |
Three Months |
|
Ended |
Ended |
|
March 31, |
March 31, |
|
2015 |
2014 |
|
(unaudited) |
(unaudited) |
|
|
|
Revenues |
25,240 |
25,025 |
|
|
|
Cost of sales |
(13,140) |
(12,864) |
|
|
|
Gross profit |
12,100 |
12,161 |
Gross profit % |
47.9% |
48.6% |
|
|
|
Other operating income |
78 |
149 |
|
|
|
Research & development expenses |
(998) |
(1,037) |
Selling, general and administrative
expenses |
(6,287) |
(6,314) |
Indirect share based payments |
(558) |
(455) |
|
|
|
Operating profit |
4,335 |
4,504 |
|
|
|
Financial income |
1 |
43 |
Financial expenses |
(24) |
(20) |
Net financing
(expense)/income |
(23) |
23 |
|
|
|
Profit before tax |
4,312 |
4,527 |
|
|
|
Income tax expense |
(304) |
(114) |
|
|
|
Profit for the period |
4,008 |
4,413 |
|
|
|
Earnings per ADR (US cents) |
17.4 |
19.6 |
|
|
|
Diluted earnings per ADR (US cents) |
17.0 |
18.2 |
|
|
|
Weighted average no. of ADRs used in
computing basic earnings per ADR |
22,985,234 |
22,465,202 |
Weighted average no. of ADRs used in
computing diluted earnings per ADR |
23,604,244 |
24,209,680 |
The above financial statements have been prepared in accordance
with the principles of International Financial Reporting Standards
and the Company's accounting policies but do not constitute an
interim financial report as defined in IAS 34 (Interim Financial
Reporting).
Trinity Biotech
plc |
Consolidated Balance
Sheets |
|
|
|
|
March 31, |
Dec 31, |
|
2015 |
2014 |
|
US$ '000 |
US$ '000 |
|
(unaudited) |
(unaudited) |
ASSETS |
|
|
Non-current assets |
|
|
Property, plant and equipment |
17,760 |
17,877 |
Goodwill and intangible assets |
147,568 |
145,024 |
Deferred tax assets |
9,528 |
9,798 |
Other assets |
1,249 |
1,194 |
Total non-current
assets |
176,105 |
173,893 |
|
|
|
Current assets |
|
|
Inventories |
37,064 |
33,516 |
Trade and other receivables |
27,640 |
25,976 |
Income tax receivable |
221 |
351 |
Cash and cash equivalents |
5,745 |
9,102 |
Total current assets |
70,670 |
68,945 |
|
|
|
TOTAL ASSETS |
246,775 |
242,838 |
|
|
|
EQUITY AND LIABILITIES |
|
|
Equity attributable to the equity
holders of the parent |
|
|
Share capital |
1,215 |
1,204 |
Share premium |
14,393 |
12,422 |
Accumulated surplus |
188,094 |
183,375 |
Other reserves |
(2,463) |
(29) |
Total equity |
201,239 |
196,972 |
|
|
|
Current liabilities |
|
|
Income tax payable |
467 |
785 |
Trade and other payables |
20,116 |
21,197 |
Provisions |
75 |
75 |
Total current
liabilities |
20,658 |
22,057 |
|
|
|
Non-current liabilities |
|
|
Other payables |
3,205 |
2,370 |
Deferred tax liabilities |
21,673 |
21,439 |
Total non-current
liabilities |
24,878 |
23,809 |
|
|
|
TOTAL LIABILITIES |
45,536 |
45,866 |
|
|
|
TOTAL EQUITY AND
LIABILITIES |
246,775 |
242,838 |
The above financial statements have been prepared in accordance
with the principles of International Financial Reporting Standards
and the Company's accounting policies but do not constitute an
interim financial report as defined in IAS 34 (Interim Financial
Reporting).
Trinity Biotech
plc |
Consolidated Statement
of Cash Flows |
|
|
|
(US$000's) |
Three Months |
Three Months |
|
Ended |
Ended |
|
March 31, |
March 31, |
|
2015 |
2014 |
|
(unaudited) |
(unaudited) |
|
|
|
Cash and cash equivalents at
beginning of period |
9,102 |
22,317 |
|
|
|
Operating cash flows before changes in
working capital |
6,298 |
4,993 |
Changes in working capital |
(4,322) |
(4,212) |
|
|
|
Cash generated from operations |
1,976 |
781 |
|
|
|
Net Interest and Income taxes
(paid)/received |
(108) |
2 |
|
|
|
Capital Expenditure & Financing
(net) |
(4,113) |
(5,042) |
|
|
|
Free cash flow |
(2,245) |
(4,259) |
|
|
|
Payment of HIV-2 licence fee |
(1,112) |
-- |
|
|
|
Deferred consideration paid |
-- |
(1,050) |
|
|
|
Cash and cash equivalents at end of
period |
5,745 |
17,008 |
The above financial statements have been prepared in accordance
with the principles of International Financial Reporting Standards
and the Company's accounting policies but do not constitute an
interim financial report as defined in IAS 34 (Interim Financial
Reporting).
CONTACT: Trinity Biotech plc
Kevin Tansley
353)-1-2769800
E-mail: kevin.tansley@trinitybiotech.com
Lytham Partners LLC
Joe Diaz, Joe Dorame & Robert Blum
602-889-9700
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Apr 2023 to Apr 2024